Patent US5962429A successfully refreshed from Google Patents.
US5962429A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Complexes of adenovirus with cationic molecules
Assignee: University of Iowa Research Foundation
•
Filing: 1996-11-22
•
Granted: 1999-10-05
•
Expires: 2016-11-22
Abstract
Abstract The present invention provides noncovalent complexes of cationic molecules and adenoviral vectors containing a transgene. The complexes of the invention exhibit increased efficiency of gene transfer to a target cell relative to adenoviral vectors alone. Methods of making and using the complexes are also provided. A method of delivering cystic fibrosis transmembrane conductance regulator to a CF patient utilizing a complex of cationic molecules and adenoviral vectors containing a transgene encoding a CFTR protein is provided.
Inventors
- 👤 Michael J. Welsh
- 👤 Allen J. Fasbender
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 11:26
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/85; C12N15/86; A; A61; A61K; A61K48/00; C12N2710/00; C12N2710/00011; C12N2710/10011; C12N2710/10311; C12N2710/10341; C12N2710/10343; C12N2810/00; C12N2810/10; C12N2810/40
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
39 words
A noncovalent complex comprising cationic lipids, or cationic polymers selected from the group consisting of poly-L-lysine, polyethyleneimine, DEAE-dextran, histone and cationic dendrimer, and adenoviral particles wherein said adenoviral particles comprise a transgene operably linked to an expression control sequence.
Claim 2
Dependent Claim
39 words
A noncovalent complex comprising cationic lipids, or cationic polymers selected from the group consisting of poly-L-lysine, polyethyleneimine, DEAE-dextran, histone and cationic dendrimer, and adenoviral particles wherein said adenoviral particles comprise a transgene operably linked to an expression control sequence.
Claim 3
Dependent Claim
35 words
The noncovalent complex of claim 1 wherein said cationic lipids are selected from the group consisting of DC-Chol, GL-67, GL-53, DOSPA, DOGS, DOSPER, DOTAP, DOTMA, DMRIE, βAE-DMRIE, DDAB, LIPOFECTIN®, LIPOFECTAMINE™, LIPOFECTACE™, TRANSFECTAM®, Tfx™-50, and DMRIE-C™.
Claim 4
Dependent Claim
17 words
The noncovalent complex of claim 1 wherein said transgene encodes a cystic fibrosis transmembrane conductance regulator protein.
Claim 5
Dependent Claim
12 words
A composition comprising the noncovalent complex of claim 1 and a carrier.
Claim 6
Independent Claim
57 words
A method of making a noncovalent complex comprising cationic lipids, or cationic polymers selected from the group consisting of poly-L-lysine, polyethyleneimine, DEAE-dextran, histone and cationic dendrimer, and adenoviral particles wherein said adenoviral particles comprise a transgene operably linked to an expression control sequence, said method comprising mixing said cationic lipids or cationic polymers with said adenoviral particles.
Claim 7
Independent Claim
57 words
A method of making a noncovalent complex comprising cationic lipids, or cationic polymers selected from the group consisting of poly-L-lysine, polyethyleneimine, DEAE-dextran, histone and cationic dendrimer, and adenoviral particles wherein said adenoviral particles comprise a transgene operably linked to an expression control sequence, said method comprising mixing said cationic lipids or cationic polymers with said adenoviral particles.
Claim 8
Dependent Claim
22 words
The method of claim 5 wherein said cationic lipids or polymers and said adenoviral particles are diluted in a pharmaceutically acceptable carrier.
Claim 9
Dependent Claim
34 words
The method of claim 5 wherein said cationic lipids are selected from the group consisting of DC-Chol, GL-67, GL-53, DOSPA, DOGS, DOSPER, DOTAP, DOTMA, DMRIE, βAE-DMRIE, DDAB, LIPOFECTIN®, LIPOFECTAMINE™, LIPOFECTACE™, TRANSFECTAM®, Tfx™-50 and DMRIE-C™.
Claim 10
Dependent Claim
16 words
The method of claim 5 wherein said transgene encodes a cystic fibrosis transmembrane conductance regulator protein.
Claim 11
Independent Claim
58 words
A method for delivering a transgene to an airway epithelial cell comprising combining cationic lipids, or cationic polymers selected from the group consisting of poly-L-lysine, polyethyleneimine, DEAE-dextran, histone and cationic dendrimer, and adenoviral particles comprising said transgene operably linked to an expression control sequence to form a noncovalent complex, and introducing said complex into said airway epithelial cell.
Claim 12
Independent Claim
58 words
A method for delivering a transgene to an airway epithelial cell comprising combining cationic lipids, or cationic polymers selected from the group consisting of poly-L-lysine, polyethyleneimine, DEAE-dextran, histone and cationic dendrimer, and adenoviral particles comprising said transgene operably linked to an expression control sequence to form a noncovalent complex, and introducing said complex into said airway epithelial cell.
Claim 13
Dependent Claim
17 words
The method of claim 9 wherein said complex is introduced into said airway epithelial cell by infection.
Claim 14
Dependent Claim
34 words
The method of claim 11 wherein said cationic lipids are selected from the group consisting of DC-Chol, GL-67, GL-53, DOSPA, DOGS, DOSPER, DOTAP, DOTMA, DMRIE, βAE-DMRIE DDAB, LIPOFECTIN®, LIPOFECTAMINE™, LIPOFECTACE™, TRANSFECTAM®, Tfx™-50 and DMRIE-C™.
Claim 15
Dependent Claim
14 words
The method of claim 9 wherein said transgene encodes cystic fibrosis transmembrane conductance regulator.
Claim 16
Independent Claim
106 words
A method of providing cystic fibrosis transmembrane conductance regulator to airway epithelial cells of a cystic fibrosis patient comprising combining cationic lipids, or cationic polymers selected from the group consisting of poly-L-lysine, polyethyleneimine, DEAE-dextran histone and cationic dendrimer, with adenoviral particles containing a transgene encoding cystic fibrosis transmembrane conductance regulator, wherein said transgene is operably linked to an expression control sequence, to form a noncovalent complex, and administering said complex to the airway epithelial cells of said cystic fibrosis patient, in an amount and under conditions whereby said transgene is expressed and a functional chloride channel is produced in the airway epithelial cells of said patient.
Claim 17
Independent Claim
106 words
A method of providing cystic fibrosis transmembrane conductance regulator to airway epithelial cells of a cystic fibrosis patient comprising combining cationic lipids, or cationic polymers selected from the group consisting of poly-L-lysine, polyethyleneimine, DEAE-dextran histone and cationic dendrimer, with adenoviral particles containing a transgene encoding cystic fibrosis transmembrane conductance regulator, wherein said transgene is operably linked to an expression control sequence, to form a noncovalent complex, and administering said complex to the airway epithelial cells of said cystic fibrosis patient, in an amount and under conditions whereby said transgene is expressed and a functional chloride channel is produced in the airway epithelial cells of said patient.
Claim 18
Dependent Claim
17 words
The method of claim 13 wherein said complex is delivered to said airway epithelial cells by inhalation.
Claim 19
Independent Claim
58 words
A method for delivering a transgene to a target cell in vitro comprising combining cationic lipids, or cationic polymers selected from the group consisting of poly-L-lysine, polyethyleneimine, DEAE-dextran, histone and cationic dendrimer, and adenoviral particles comprising said transgene operably linked to an expression control sequence to form a noncovalent complex, and introducing said complex into said target cell.
Claim 20
Independent Claim
58 words
A method for delivering a transgene to a target cell in vitro comprising combining cationic lipids, or cationic polymers selected from the group consisting of poly-L-lysine, polyethyleneimine, DEAE-dextran, histone and cationic dendrimer, and adenoviral particles comprising said transgene operably linked to an expression control sequence to form a noncovalent complex, and introducing said complex into said target cell.
Claim 21
Dependent Claim
16 words
The method of claim 15 wherein said complex is introduced into said target cell by infection.
Claim 22
Dependent Claim
34 words
The method of claim 15 wherein said cationic lipids are selected from the group consisting of DC-Chol, GL-67, GL-53, DOSPA, DOGS, DOSPER, DOTAP, DOTMA, DMRIE, βAE-DMRIE, DDAB, LIPOFECTIN®, LIPOFECTAMINE™, LIPOFECTACE™, TRANSFECTAM™, Tfx™-50 and DMRIE-C™.
References Cited (Backward Citations)
US5670488A
Cited
WO1995021259A1
Cited
WO1996003977A1
Cited
US5552309A
Cited
WO1996018372A2
Cited
WO1996022765A1
Cited
US5798250A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2002-10-04 | 2003-04-05 | 2003-10-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2006-10-04 | 2007-04-05 | 2007-10-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2010-10-04 | 2011-04-05 | 2011-10-05 | $7700.00 | Window Closed / Lapsed |